Insider Transactions in Q4 2024 at Fennec Pharmaceuticals Inc. (FENC)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 20
2024
|
Rosty Raykov |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+21.47%
|
$50,000
$2.69 P/Share
|
|
Dec 05
2024
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
796
-1.18%
|
$4,776
$6.04 P/Share
|
|
Dec 03
2024
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
1,635
-2.37%
|
$9,810
$6.13 P/Share
|
|
Dec 02
2024
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+3.41%
|
-
|
|
Dec 02
2024
|
Chris A Rallis |
SELL
Open market or private sale
|
Direct |
6,409
-10.93%
|
$38,454
$6.14 P/Share
|
|
Dec 02
2024
|
Chris A Rallis |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+14.57%
|
$20,000
$2.69 P/Share
|
|
Dec 02
2024
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,042
+0.8%
|
-
|
|
Nov 18
2024
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,816
+11.04%
|
$31,632
$2.45 P/Share
|
|
Nov 04
2024
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
2,431
-3.53%
|
$9,724
$4.31 P/Share
|
|
Oct 31
2024
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,042
+0.93%
|
-
|
|
Oct 31
2024
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+3.41%
|
-
|
|
Oct 08
2024
|
Chris A Rallis |
SELL
Open market or private sale
|
Direct |
1,406
-2.81%
|
$5,624
$4.53 P/Share
|
|
Oct 08
2024
|
Chris A Rallis |
BUY
Exercise of conversion of derivative security
|
Direct |
1,960
+3.77%
|
$3,920
$2.55 P/Share
|
|
Oct 01
2024
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
2,431
-3.53%
|
$9,724
$4.94 P/Share
|